Materiały źródłowe

• #1 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Liposarcoma is the most common soft tissue sarcoma. With its various subtypes, the natural history of this disease can vary significantly from a locally recurrent tumor to a highly malignant one carrying a poor prognosis. Progress in the understanding of the specific molecular abnormalities in liposarcoma provides greater opportunity for new treatment modalities. Although surgical resection and radiation therapy remain the keystones for the management of primary liposarcoma, the inclusion of novel agents that target known abnormalities in advanced liposarcoma enhances the potential for improved outcomes. […] Surgical resection of liposarcoma in the extremity follows oncologic principles. A goal of a wide resection with a negative margin is always desired. […] Treatment of liposarcoma with radiation is informed by randomized trials in extremity sarcoma showing improved local control with adjuvant radiation following limb-sparing surgery.

• #2 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  There are three biologic groups of liposarcoma: well- and dedifferentiated liposarcoma (WD/DDLS), myxoid/round cell liposarcoma (M/RCLS) and pleomorphic liposarcoma. […] In all three groups, complete surgical resection is central in treatment aimed at cure and is based on grade. […] Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the highly radiosensitive M/RCLS group. […] An improved understanding of the genetic aberrations that lead to liposarcoma initiation is also allowing for the rapid development of targeted therapies for liposarcoma. Among such therapies are CDK4 inhibitors in WD/DDLS and trabectedin, which prevents FUS-DDIT3 binding to DNA, in M/RCLS. […] Surgery remains the mainstay of treatment for LPS, but the three subgroups have highly variable response to systemic therapies, affecting recommendations regarding adjuvant therapy.

• #3 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  There are three biologic groups of liposarcoma: well- and dedifferentiated liposarcoma (WD/DDLS), myxoid/round cell liposarcoma (M/RCLS) and pleomorphic liposarcoma. […] In all three groups, complete surgical resection is central in treatment aimed at cure and is based on grade. […] Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the highly radiosensitive M/RCLS group. […] An improved understanding of the genetic aberrations that lead to liposarcoma initiation is also allowing for the rapid development of targeted therapies for liposarcoma. Among such therapies are CDK4 inhibitors in WD/DDLS and trabectedin, which prevents FUS-DDIT3 binding to DNA, in M/RCLS. […] Surgery remains the mainstay of treatment for LPS, but the three subgroups have highly variable response to systemic therapies, affecting recommendations regarding adjuvant therapy.

• #4 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  Liposarcoma has a number of different subtypes (ie, well differentiated, dedifferentiated, myxoid/round cell, pleomorphic), and their response to chemotherapy is not well documented. […] This retrospective analysis suggested that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, in particular dedifferentiated and well-differentiated tumors. […] For liposarcomas, radiation therapy may be a valuable adjunct to surgery, especially in those of the myxoid variant. […] The use of chemotherapy in liposarcomas remains experimental. […] Although surgical resection is the mainstay of curative treatment, patients with large high-grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation. […] Trabectedin (Yondelis) was approved in November 2015 in the United States for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen.

• #5 Liposarcoma: Symptoms, Causes, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

  Liposarcoma is a group of very rare cancers that usually begin in fat cells in your arms and legs. Healthcare providers treat liposarcoma with surgery to remove tumors. Some types of liposarcoma may come back, requiring additional treatment and long-term follow up to catch new tumors before they can spread. […] Healthcare providers treat liposarcoma with surgery to remove tumors. Some types of liposarcoma may come back, requiring additional treatment and long-term follow up to catch new liposarcomas before they can spread. […] Liposarcoma treatment depends on the liposarcoma type, whether the cancer has spread and, if so, where it has spread. You may have a combination of more than one type of treatment for the disease. Treatments may include: […] Surgery: A surgeon removes the tumor and surrounding healthy tissue, including microscopic tumor cells.

• #6 Liposarcoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/liposarcoma/diagnosis-treatment/drc-20352635

  Treatments for liposarcoma include: […] Surgery. The goal of surgery is to remove all of the cancer cells. Whenever possible, surgeons work to remove the entire liposarcoma without damaging any surrounding organs. […] If a liposarcoma grows to involve nearby organs, removal of the entire liposarcoma may not be possible. In those situations, your health care team may recommend other treatments to shrink the liposarcoma. That will make it easier to remove during an operation. […] Radiation therapy. Radiation therapy uses powerful energy beams to kill cancer cells. The energy can come from X-rays, protons or other sources. Radiation may be used after surgery to kill any cancer cells that remain. Radiation also may be used before surgery to shrink a tumor to make it more likely that surgeons can remove the entire tumor.

• #7 Liposarcoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/liposarcoma/diagnosis-treatment/drc-20352635

  Treatments for liposarcoma include: […] Surgery. The goal of surgery is to remove all of the cancer cells. Whenever possible, surgeons work to remove the entire liposarcoma without damaging any surrounding organs. […] If a liposarcoma grows to involve nearby organs, removal of the entire liposarcoma may not be possible. In those situations, your health care team may recommend other treatments to shrink the liposarcoma. That will make it easier to remove during an operation. […] Radiation therapy. Radiation therapy uses powerful energy beams to kill cancer cells. The energy can come from X-rays, protons or other sources. Radiation may be used after surgery to kill any cancer cells that remain. Radiation also may be used before surgery to shrink a tumor to make it more likely that surgeons can remove the entire tumor.

• #8 Liposarcoma – What You Need to Know

  https://www.drugs.com/cg/liposarcoma.html

  Liposarcoma is a type of cancer that most often develops from fat cells. […] How is liposarcoma treated? […] Chemotherapy: This medicine works by killing cancer cells. Your healthcare provider may use chemotherapy to make your tumor smaller before surgery. Your healthcare provider may also give you chemotherapy after surgery to kill any cancer cells that remain. […] Radiation: Radiation kills cancer cells and prevents the cancer from spreading. Radiation may also help stop your cancer from coming back after surgery. You may need radiation before, during, or after surgery. […] Surgery: You may need surgery to remove your tumor and some of the tissue around it. A graft may be used to replace bone or tissue that has been removed. A graft is a piece of tissue from another area of your body or from a donor. In some cases, your healthcare provider may need to amputate (remove) your limb to remove your tumor.

• #9 Liposarcoma: Symptoms, Causes, Stages, Diagnosis and Treatment – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/liposarcoma

  For well-differentiated liposarcomas (WDLPS), which are typically less aggressive, complete surgical resection with clear margins is the standard treatment. However, achieving negative margins can be challenging in anatomically complex areas, such as the retroperitoneum, due to the proximity of vital structures. […] In dedifferentiated liposarcomas (DDLPS), which are more aggressive and have a higher propensity for recurrence, wide or radical surgical excision is recommended. […] Radiation therapy plays a significant role in the management of liposarcoma, particularly in reducing tumor size before surgery and decreasing the risk of recurrence. This approach is especially pertinent for subtypes like myxoid liposarcoma, which exhibit heightened sensitivity to radiation. […] Administering radiation therapy before surgery, known as neoadjuvant therapy, aims to shrink tumors, facilitating their removal and potentially allowing for less extensive surgical procedures.

• #10 Well-Differentiated Liposarcoma – Sarcoma Oncology Center

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/well-differentiated-liposarcoma/

  Surgery is the primary treatment for well-differentiated liposarcoma and is often the most effective approach. During surgery, the goal is to remove the tumor along with a margin of healthy tissue surrounding it. This practice helps ensure that any microscopic cancer cells not visible to the naked eye are also removed, reducing the risk of recurrence. […] Radiation therapy may be used alongside surgery, particularly in such cases where achieving clear margins is difficult or if the tumor is located in a sensitive area. […] Chemotherapy is generally not effective for WDLS. […] Ongoing clinical trials are exploring innovative therapies, including CDK4 and MDM2 inhibitors, for patients with advanced cases. These emerging treatments offer hope for improving outcomes in challenging cases.

• #11 Liposarcoma: Symptoms, Causes, Stages, Diagnosis and Treatment – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/liposarcoma

  For well-differentiated liposarcomas (WDLPS), which are typically less aggressive, complete surgical resection with clear margins is the standard treatment. However, achieving negative margins can be challenging in anatomically complex areas, such as the retroperitoneum, due to the proximity of vital structures. […] In dedifferentiated liposarcomas (DDLPS), which are more aggressive and have a higher propensity for recurrence, wide or radical surgical excision is recommended. […] Radiation therapy plays a significant role in the management of liposarcoma, particularly in reducing tumor size before surgery and decreasing the risk of recurrence. This approach is especially pertinent for subtypes like myxoid liposarcoma, which exhibit heightened sensitivity to radiation. […] Administering radiation therapy before surgery, known as neoadjuvant therapy, aims to shrink tumors, facilitating their removal and potentially allowing for less extensive surgical procedures.

• #12 Liposarcoma – Rein in Sarcoma

  https://www.reininsarcoma.org/liposarcoma/

  Local control with surgical resection is the cornerstone of liposarcoma treatment. The goal is to achieve 1 cm of tumor-free margins on the resected mass. Surgery alone is often curative of low grade tumors of the extremities and chest wall. If the tumor is 5 cm, high grade, and deep to the fascia, the treatment team is more likely to use radiation in conjunction with surgery. This can be given intraoperatively, prior to surgery (neoadjuvant), or after surgery (adjuvant). Amputation of an extremity is rarely necessary given these treatment options. […] Retroperitoneal liposarcoma is more difficult to treat due to the inherent difficulty in achieving complete surgical resection and the limitation of radiation therapy due to tolerance of abdominal organs in this space. The best chance of achieving a cure is with wide resection of the primary tumor. This sometimes includes removing adjacent organs such as the kidney or part of the bowel. Even with aggressive surgery, these tumors have a high tendency of recurrence. Patients may undergo multiple surgical resections in the management of this cancer. Intraoperative radiation and/or neoadjuvant radiation therapy are considered in conjunction with surgery depending on the location and clinical situation.

• #13 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #14 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  Myxoid liposarcoma treatment is unique to each patient. […] Treatment for myxoid liposarcoma may include surgery, radiation therapy and/or chemotherapy. […] About 50% of the time, we find myxoid liposarcoma before it has spread. We call this localized cancer. In these cases, surgery is the most common treatment. We want to remove the tumor with a rim of normal tissue surrounding it. […] Radiation therapy may be used before surgery to shrink a tumor that has not spread and to lower the risk of recurrence. It can also be used after surgery to lower the risk of recurrence. […] Chemotherapy may be used for larger tumors, more advanced myxoid liposarcoma or cancer that has come back after surgery. […] We may use chemotherapy and radiation therapy before surgery for localized tumors. Chemotherapy may be used in advanced myxoid liposarcoma to control the tumors for as long as possible when surgery is not an option.

• #15 Liposarcoma – Rein in Sarcoma

  https://www.reininsarcoma.org/liposarcoma/

  Local control with surgical resection is the cornerstone of liposarcoma treatment. The goal is to achieve 1 cm of tumor-free margins on the resected mass. Surgery alone is often curative of low grade tumors of the extremities and chest wall. If the tumor is 5 cm, high grade, and deep to the fascia, the treatment team is more likely to use radiation in conjunction with surgery. This can be given intraoperatively, prior to surgery (neoadjuvant), or after surgery (adjuvant). Amputation of an extremity is rarely necessary given these treatment options. […] Retroperitoneal liposarcoma is more difficult to treat due to the inherent difficulty in achieving complete surgical resection and the limitation of radiation therapy due to tolerance of abdominal organs in this space. The best chance of achieving a cure is with wide resection of the primary tumor. This sometimes includes removing adjacent organs such as the kidney or part of the bowel. Even with aggressive surgery, these tumors have a high tendency of recurrence. Patients may undergo multiple surgical resections in the management of this cancer. Intraoperative radiation and/or neoadjuvant radiation therapy are considered in conjunction with surgery depending on the location and clinical situation.

• #16 Liposarcoma – Rein in Sarcoma

  https://www.reininsarcoma.org/liposarcoma/

  Local control with surgical resection is the cornerstone of liposarcoma treatment. The goal is to achieve 1 cm of tumor-free margins on the resected mass. Surgery alone is often curative of low grade tumors of the extremities and chest wall. If the tumor is 5 cm, high grade, and deep to the fascia, the treatment team is more likely to use radiation in conjunction with surgery. This can be given intraoperatively, prior to surgery (neoadjuvant), or after surgery (adjuvant). Amputation of an extremity is rarely necessary given these treatment options. […] Retroperitoneal liposarcoma is more difficult to treat due to the inherent difficulty in achieving complete surgical resection and the limitation of radiation therapy due to tolerance of abdominal organs in this space. The best chance of achieving a cure is with wide resection of the primary tumor. This sometimes includes removing adjacent organs such as the kidney or part of the bowel. Even with aggressive surgery, these tumors have a high tendency of recurrence. Patients may undergo multiple surgical resections in the management of this cancer. Intraoperative radiation and/or neoadjuvant radiation therapy are considered in conjunction with surgery depending on the location and clinical situation.

• #17 Soft Tissue Sarcoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq

  Effective treatment of retroperitoneal sarcomas requires removal of all gross disease while sparing adjacent viscera not invaded by tumor. […] In the setting of distant metastasis, surgery may be associated with long-term disease-free survival (DFS) in patients with pulmonary metastasis and optimal underlying disease biology. […] Chemotherapy remains controversial. […] The role of adjuvant chemotherapy remains controversial. […] The addition of ifosfamide (with mesna) to doxorubicin increases response rates and progression-free survival (PFS), but it has not been shown to improve overall survival (OS). […] Trabectedin is an FDA-approved option for second-line treatment of patients with advanced liposarcoma and leiomyosarcoma. […] Eribulin is a microtubule inhibitor that the FDA approved in 2016 to treat patients with unresectable or metastatic liposarcoma, who previously received anthracycline-containing chemotherapy. […] Immune checkpoint inhibitor therapy has shown some activity in selected soft tissue sarcoma subtypes, but the factors that may predict activity remain unknown.

• #18 Liposarcoma: Symptoms, Causes, Stages, Diagnosis and Treatment – OncoDaily

  https://oncodaily.com/oncolibrary/cancer-types/liposarcoma

  For well-differentiated liposarcomas (WDLPS), which are typically less aggressive, complete surgical resection with clear margins is the standard treatment. However, achieving negative margins can be challenging in anatomically complex areas, such as the retroperitoneum, due to the proximity of vital structures. […] In dedifferentiated liposarcomas (DDLPS), which are more aggressive and have a higher propensity for recurrence, wide or radical surgical excision is recommended. […] Radiation therapy plays a significant role in the management of liposarcoma, particularly in reducing tumor size before surgery and decreasing the risk of recurrence. This approach is especially pertinent for subtypes like myxoid liposarcoma, which exhibit heightened sensitivity to radiation. […] Administering radiation therapy before surgery, known as neoadjuvant therapy, aims to shrink tumors, facilitating their removal and potentially allowing for less extensive surgical procedures.

• #19 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #20 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #21 Liposarcoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/liposarcoma/diagnosis-treatment/drc-20352635

  Treatments for liposarcoma include: […] Surgery. The goal of surgery is to remove all of the cancer cells. Whenever possible, surgeons work to remove the entire liposarcoma without damaging any surrounding organs. […] If a liposarcoma grows to involve nearby organs, removal of the entire liposarcoma may not be possible. In those situations, your health care team may recommend other treatments to shrink the liposarcoma. That will make it easier to remove during an operation. […] Radiation therapy. Radiation therapy uses powerful energy beams to kill cancer cells. The energy can come from X-rays, protons or other sources. Radiation may be used after surgery to kill any cancer cells that remain. Radiation also may be used before surgery to shrink a tumor to make it more likely that surgeons can remove the entire tumor.

• #22 Liposarcoma – Diagnosis & Disease Information

  https://www.cancertherapyadvisor.com/ddi/liposarcoma/

  Liposarcoma treatment is tailored to the subtype, location, and grade of the tumor, as well as the patients overall health. Surgical resection is the primary treatment for patients with localized liposarcoma and often is performed in addition to radiation therapy. The primary goals of treatment are to achieve complete surgical resection of the tumor, minimize the risk of recurrence, and manage metastatic disease (when present). […] Surgical resection is the cornerstone of treatment for localized liposarcoma, with the goal of completely excising the tumor with wide margins to minimize the risk of recurrence. The specific surgical approach used is based on the tumors size, location, and proximity to adjacent structures. […] Radiation therapy serves a crucial role in the management of liposarcoma as a neoadjuvant and/or adjuvant treatment. Neoadjuvant radiation therapy may be used before surgery to shrink the tumor, making surgical resection more feasible and potentially less invasive. Postoperatively, adjuvant radiation therapy is often employed to lower the likelihood of local recurrence, particularly for tumors situated in difficult anatomical locations or those with narrow surgical margins.

• #23 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #24 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  Myxoid liposarcoma treatment is unique to each patient. […] Treatment for myxoid liposarcoma may include surgery, radiation therapy and/or chemotherapy. […] About 50% of the time, we find myxoid liposarcoma before it has spread. We call this localized cancer. In these cases, surgery is the most common treatment. We want to remove the tumor with a rim of normal tissue surrounding it. […] Radiation therapy may be used before surgery to shrink a tumor that has not spread and to lower the risk of recurrence. It can also be used after surgery to lower the risk of recurrence. […] Chemotherapy may be used for larger tumors, more advanced myxoid liposarcoma or cancer that has come back after surgery. […] We may use chemotherapy and radiation therapy before surgery for localized tumors. Chemotherapy may be used in advanced myxoid liposarcoma to control the tumors for as long as possible when surgery is not an option.

• #25 Soft Tissue Sarcoma: Liposarcoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma/types/liposarcoma

  Liposarcoma is a type of cancer known as soft tissue sarcoma. It begins in the fatty tissues of the body. […] The main treatment for liposarcoma is surgery to remove the tumor. Liposarcoma can begin in many different parts of the body. The surgery thats right for you depends on the exact size and location of the tumor. […] Doctors may also recommend radiation, chemotherapy, or other drug therapies. These treatments can help prevent the tumor from coming back. […] Which combination of treatments is right for you depends on the unique characteristics of the tumor. MSKs liposarcoma specialists tend to recommend radiation for people with myxoid tumors but not for people with well-differentiated tumors. Drug therapies can be beneficial, especially for myxoid and round cell tumors. […] Liposarcoma is also known for its ability to regrow after treatment. It can come back months to decades after the initial diagnosis. Thats why people should receive ongoing follow-up care to monitor for a return of liposarcoma.

• #26 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  Adjuvant radiation is employed to reduce risk of local recurrence in the case of high-grade DDLS of the extremity that is greater than 5 cm in diameter or after R1 resection that cannot be improved without causing major morbidity. […] Given poor rates of response, systemic therapy is generally reserved for unresectable disease, in some instances preoperatively for marginally resectable disease, or in the context of metastatic disease. […] The role for radiation is debatable; radiation is considered at many institutions because of high rates of local recurrence. […] The efficacy of neoadjuvant radiation has been partially defined by two prospective series with a combined 72 patients, though only 40% of the patients had liposarcoma and 25% had recurrent disease. […] Most STS specialists agree on the need for complete gross resection of retroperitoneal WD/DDLS, and as in the extremity, adjuvant systemic therapy is rarely considered.

• #27 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #28 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  Liposarcoma has a number of different subtypes (ie, well differentiated, dedifferentiated, myxoid/round cell, pleomorphic), and their response to chemotherapy is not well documented. […] This retrospective analysis suggested that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, in particular dedifferentiated and well-differentiated tumors. […] For liposarcomas, radiation therapy may be a valuable adjunct to surgery, especially in those of the myxoid variant. […] The use of chemotherapy in liposarcomas remains experimental. […] Although surgical resection is the mainstay of curative treatment, patients with large high-grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation. […] Trabectedin (Yondelis) was approved in November 2015 in the United States for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen.

• #29 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  Liposarcoma has a number of different subtypes (ie, well differentiated, dedifferentiated, myxoid/round cell, pleomorphic), and their response to chemotherapy is not well documented. […] This retrospective analysis suggested that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, in particular dedifferentiated and well-differentiated tumors. […] For liposarcomas, radiation therapy may be a valuable adjunct to surgery, especially in those of the myxoid variant. […] The use of chemotherapy in liposarcomas remains experimental. […] Although surgical resection is the mainstay of curative treatment, patients with large high-grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation. […] Trabectedin (Yondelis) was approved in November 2015 in the United States for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen.

• #30

  https://link.springer.com/article/10.1007/s11864-023-01057-4

  Myxoid/round-cell liposarcoma (MRCL) account for 30% of liposarcomas and are the most chemo-sensitive subtype of liposarcoma. The overall response rate (ORR) by RECIST with anthracycline-based chemotherapy is around 40% and with trabectedin is 20%, although response is higher when captured by CHOI criteria. Anthracycline-based combination chemotherapy regimens remain the standard of care first-line treatment option. However, trabectedin is also effective and may be considered in the first-line setting when anthracyclines cannot be prescribed. Beyond chemotherapy, new therapeutic classes are being developed, including autologous adoptive modified T cell receptor cellular therapies which have shown promising results thus far. Early phase trials have shown encouraging results with up to 40% ORR and a median progression-free survival up to 8.7 months. […] Updated NCCN guidelines include recommendation of anthracycline-based chemotherapy as first-line systemic therapy option, with trabectedin as an alternate therapeutic option.

• #31 Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard | Scientific Reports

  https://www.nature.com/articles/s41598-017-12132-w

  Benefit from chemotherapy for well-differentiated/de-differentiated (WD/DD) liposarcomas has been reported to be minimal, however traditional response criteria may not adequately capture positive treatment effect. […] To date, surgery remains the mainstay of treatment for WD/DD liposarcomas of the RP, however local recurrence rates can be 80%. […] Benefit from chemotherapy for WD/DD liposarcomas has been reported to be minimal and limited to DD areas, with response rates reported 12%, and hence systemic therapy is not frequently utilized in the primary or recurrent setting. […] Combination chemotherapy yields a response rate of 24% and a clinical benefit rate (CR/PR/SD6 months) of 44%, higher than previously reported in DD liposarcoma. […] The overall ORR of 21% within our study was significantly higher than previously reported in WD/DD liposarcoma.

• #32 Well-Differentiated Liposarcoma – Sarcoma Oncology Center

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/well-differentiated-liposarcoma/

  Surgery is the primary treatment for well-differentiated liposarcoma and is often the most effective approach. During surgery, the goal is to remove the tumor along with a margin of healthy tissue surrounding it. This practice helps ensure that any microscopic cancer cells not visible to the naked eye are also removed, reducing the risk of recurrence. […] Radiation therapy may be used alongside surgery, particularly in such cases where achieving clear margins is difficult or if the tumor is located in a sensitive area. […] Chemotherapy is generally not effective for WDLS. […] Ongoing clinical trials are exploring innovative therapies, including CDK4 and MDM2 inhibitors, for patients with advanced cases. These emerging treatments offer hope for improving outcomes in challenging cases.

• #33 Histology driven systemic therapy of liposarcoma—ready for prime time? – Grethlein – Translational Gastroenterology and Hepatology

  https://tgh.amegroups.org/article/view/4712/html

  Liposarcomas are a subtype of soft tissue sarcomas arising from adipocytes. This article reviews what has been reported regarding the responsiveness of these sarcoma subtypes to traditional and newly developed systemic therapies. Overall survival for patients with advanced liposarcoma treated with systemic therapy is 16.3 months. The article addresses our progress toward the goal of improved liposarcoma outcomes through tailored interventions. Patients with liposarcoma (n=105) received first line chemotherapy with doxorubicin alone (61.8%), doxorubicin and ifosfamide (14.3%), docetaxel and gemcitabine (2.9%), docetaxel alone (2.9%) and trabectedin (2.9%). Responses were deemed complete response (CR) (3.8%), partial response (PR) (32.4%), stable disease (30.5%) and progressive disease (30.5%). The median overall survival was 16.3 months. A retrospective analysis of 16,370 patients with stage III soft tissue sarcoma treated between 1998 and 2012 in the United States was performed on the National Cancer Data Base (NCDB). There was a statistically significant (P0.001) superior overall survival for those receiving chemotherapy, compared with those who did not receive chemotherapy (82.7 versus 51.3 months). The benefit was most pronounced in pleiomorphic undifferentiated sarcoma patients. The use of molecular diagnostic techniques is better characterizing these groups. Doxorubicin, ifosfamide, gemcitabine, docetaxel, trabectedin and eribulin are now considered to be some of the most active agents in the treatment of soft tissue sarcomas in general, and liposarcoma in specific. The value of adjuvant or neoadjuvant therapy for sarcoma is tied not only to histologic subtype, but also to location. The role of adjuvant chemotherapy was studied in a phase three Italian Sarcoma Group trial in patients with high risk superficial trunk or limb soft tissue sarcoma. Patients received 3 neoadjuvant cycles of epirubicin and ifosfamide and either no additional chemotherapy or 2 cycles in the adjuvant setting. There was no significant difference in 10-year overall survival between the groups. In myxoid-round cell liposarcoma, however, relapse free survival was similar with trabectedin and the standard epirubicin with ifosfamide. In 2018, there is insufficient evidence to recommend selection of systemic therapy on the basis of the histologic subtype in most liposarcomas. An exception is MLPSs, which demonstrate particular sensitivity to trabectedin, though they generally have superior response to other agents as well.

• #34 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  Doxorubicin-based chemotherapy (either as a single agent or with ifosfamide) has been a standard treatment for recurrent STS for many years. […] While a range of systemic options are available for patients with advanced WD/DDLS, they appear to have limited efficacy, at least compared to myxoid and pleomorphic liposarcomas. […] Significant effort has been made to identify targeted therapies for the disease by understanding the genetic events that drive tumorigenesis. […] Trabectedin has been available in Europe since 2007 and was FDA-approved in the US in 2015 based on a randomized phase 3 trial. […] The newest drug for liposarcoma is eribulin, a novel microtubule inhibitor, which was approved by the FDA in 2016 based on a large phase 3 study comparing eribulin to dacarbazine. […] Given this fact, our practice has been to treat eligible patients and tumors 5cm in diameter with neoadjuvant chemotherapy before surgical resection.

• #35 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  Liposarcoma has a number of different subtypes (ie, well differentiated, dedifferentiated, myxoid/round cell, pleomorphic), and their response to chemotherapy is not well documented. […] This retrospective analysis suggested that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, in particular dedifferentiated and well-differentiated tumors. […] For liposarcomas, radiation therapy may be a valuable adjunct to surgery, especially in those of the myxoid variant. […] The use of chemotherapy in liposarcomas remains experimental. […] Although surgical resection is the mainstay of curative treatment, patients with large high-grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation. […] Trabectedin (Yondelis) was approved in November 2015 in the United States for unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have received a prior anthracycline-containing regimen.

• #36 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  Doxorubicin-based chemotherapy (either as a single agent or with ifosfamide) has been a standard treatment for recurrent STS for many years. […] While a range of systemic options are available for patients with advanced WD/DDLS, they appear to have limited efficacy, at least compared to myxoid and pleomorphic liposarcomas. […] Significant effort has been made to identify targeted therapies for the disease by understanding the genetic events that drive tumorigenesis. […] Trabectedin has been available in Europe since 2007 and was FDA-approved in the US in 2015 based on a randomized phase 3 trial. […] The newest drug for liposarcoma is eribulin, a novel microtubule inhibitor, which was approved by the FDA in 2016 based on a large phase 3 study comparing eribulin to dacarbazine. […] Given this fact, our practice has been to treat eligible patients and tumors 5cm in diameter with neoadjuvant chemotherapy before surgical resection.

• #37 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  In January 2016, eribulin (Halaven), a microtubule inhibitor, was approved by the US Food and Drug Administration (FDA) for unresectable or metastatic liposarcoma in patients who received a prior anthracycline-containing regimen. […] Comprehensive genomic profiling may facilitate targeted therapy for individual liposarcomas in the future.

• #38 Liposarcoma: multimodality management and future targeted therapies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5010855/

  Doxorubicin-based chemotherapy (either as a single agent or with ifosfamide) has been a standard treatment for recurrent STS for many years. […] While a range of systemic options are available for patients with advanced WD/DDLS, they appear to have limited efficacy, at least compared to myxoid and pleomorphic liposarcomas. […] Significant effort has been made to identify targeted therapies for the disease by understanding the genetic events that drive tumorigenesis. […] Trabectedin has been available in Europe since 2007 and was FDA-approved in the US in 2015 based on a randomized phase 3 trial. […] The newest drug for liposarcoma is eribulin, a novel microtubule inhibitor, which was approved by the FDA in 2016 based on a large phase 3 study comparing eribulin to dacarbazine. […] Given this fact, our practice has been to treat eligible patients and tumors 5cm in diameter with neoadjuvant chemotherapy before surgical resection.

• #39 Liposarcoma | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/liposarcoma

  Chemotherapy may be used after surgery to kill any cancer cells that remain. It also may be used before surgery to shrink a tumor. Chemotherapy is sometimes combined with radiation therapy. […] Clinical trials. Clinical trials are studies of new treatments. These studies give you a chance to try the latest treatment options. The risk of side effects may not be known. Ask a member of your health care team whether you can participate in a clinical trial.

• #40 Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard | Scientific Reports

  https://www.nature.com/articles/s41598-017-12132-w

  Benefit from chemotherapy for well-differentiated/de-differentiated (WD/DD) liposarcomas has been reported to be minimal, however traditional response criteria may not adequately capture positive treatment effect. […] To date, surgery remains the mainstay of treatment for WD/DD liposarcomas of the RP, however local recurrence rates can be 80%. […] Benefit from chemotherapy for WD/DD liposarcomas has been reported to be minimal and limited to DD areas, with response rates reported 12%, and hence systemic therapy is not frequently utilized in the primary or recurrent setting. […] Combination chemotherapy yields a response rate of 24% and a clinical benefit rate (CR/PR/SD6 months) of 44%, higher than previously reported in DD liposarcoma. […] The overall ORR of 21% within our study was significantly higher than previously reported in WD/DD liposarcoma.

• #41 Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard | Scientific Reports

  https://www.nature.com/articles/s41598-017-12132-w

  Benefit from chemotherapy for well-differentiated/de-differentiated (WD/DD) liposarcomas has been reported to be minimal, however traditional response criteria may not adequately capture positive treatment effect. […] To date, surgery remains the mainstay of treatment for WD/DD liposarcomas of the RP, however local recurrence rates can be 80%. […] Benefit from chemotherapy for WD/DD liposarcomas has been reported to be minimal and limited to DD areas, with response rates reported 12%, and hence systemic therapy is not frequently utilized in the primary or recurrent setting. […] Combination chemotherapy yields a response rate of 24% and a clinical benefit rate (CR/PR/SD6 months) of 44%, higher than previously reported in DD liposarcoma. […] The overall ORR of 21% within our study was significantly higher than previously reported in WD/DD liposarcoma.

• #42 Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard | Scientific Reports

  https://www.nature.com/articles/s41598-017-12132-w

  Standard chemotherapy is effective and yields higher response rates than previously reported in WD/DD liposarcoma of the retroperitoneum. […] Combination chemotherapy should be considered in DD liposarcoma when tumor shrinkage is critical, especially in those patients with borderline-resectable tumors.

• #43 Alliance –

  https://allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/News-FeaturedTrial2-June2017

  Efatutazone induces liposarcoma cell death by activating a protein called PPAR-gamma. […] Treatment for such advanced patients is generally chemotherapy, and while for many patients with liposarcomas, chemotherapy can be effective, the side effects are significant, and the benefits can be short lived. […] Alliance A091202 will study how well efatutazone dihydrochloride works in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery. […] This study is for patients age 18 and older. […] How will patients be treated on this trial? This is a single-arm study. All patients will receive efatutazone orally. Treatment will continue until disease progression or unacceptable adverse event.

• #44 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Liposarcoma is the most common soft tissue sarcoma. With its various subtypes, the natural history of this disease can vary significantly from a locally recurrent tumor to a highly malignant one carrying a poor prognosis. Progress in the understanding of the specific molecular abnormalities in liposarcoma provides greater opportunity for new treatment modalities. Although surgical resection and radiation therapy remain the keystones for the management of primary liposarcoma, the inclusion of novel agents that target known abnormalities in advanced liposarcoma enhances the potential for improved outcomes. […] Surgical resection of liposarcoma in the extremity follows oncologic principles. A goal of a wide resection with a negative margin is always desired. […] Treatment of liposarcoma with radiation is informed by randomized trials in extremity sarcoma showing improved local control with adjuvant radiation following limb-sparing surgery.

• #45 Recent advances in the management of liposarcoma

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5224678/

  Myxoid liposarcoma is highly radiosensitive, and dramatic responses with pre-operative radiation have been reported. […] There is evidence of differential response and sensitivity to chemotherapy based on liposarcoma subtype. […] Several newer agents have become useful in consideration of patients with metastatic disease. Both trabectedin and eribulin have received recent FDA approval for application in the second-line setting for liposarcoma. […] Targeted therapy for advanced liposarcoma has shown promise early on. […] The main treatment options for primary disease are surgical or a combination of surgery and radiation. Systemic treatment management has been improved somewhat by the approval of several new agents and the potential of targeted therapy through a more complete knowledge of the molecular genomic basis for this rare malignancy.

• #46 Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment

  https://www.jcancer.org/v11p0100.htm

  Liposarcoma is a malignant tumor of mesenchymal origin with significant tissue diversity. It is not sensitive to traditional radiotherapy and chemotherapy and has a poor prognosis. […] This study reviews the present research status and progress of cellular and molecular alterations of liposarcoma and corresponding clinical treatment progress. […] Clinically, the curative management for localized disease is surgical resection, combined with or without radiotherapy. Systemic treatment with chemotherapy and molecular targeted agents is one of the main therapeutic modalities in patients with advanced or metastatic disease. […] In WDL/DDL, CDK4 is continuously amplified in about 90% of cases, and a CDK4/6 inhibitor, palbociclib, showed certain efficacy in the treatment of advanced CDK4+ WDL/DDL, for the 66% progression-free survival (PFS) rate at 12 weeks, and the median PFS was 18 weeks.

• #47 New hope for MDM2 inhibition in liposarcomas?

  https://dailyreporter.esmo.org/esmo-sarcoma-and-rare-cancers-congress-2024/highlights/new-hope-for-mdm2-inhibition-in-liposarcomas

  An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited […] According to results from a phase Ia/b trial presented at the ESMO Sarcoma and Rare Cancers Congress 2024, the MDM2p53 antagonist, brigimadlin, was associated with a preliminary median progression-free survival (PFS) of 8.1 months in 85 response-evaluable patients with MDM2-amplified advanced dedifferentiated liposarcoma (DDLPS) […] In another presentation from a different cohort of patients in the same phase Ia/b trial, a preliminary median PFS of 25.1 months was observed in 31 response-evaluable patients with MDM2-amplified well-differentiated LPS (WDLPS) […] Patients with DDLPS generally respond poorly to standard first-line doxorubicin treatment, with disease stabilisation being the most common positive outcome, so the fact that 16 patients achieved a response with brigimadlin is particularly encouraging

• #48 New hope for MDM2 inhibition in liposarcomas?

  https://dailyreporter.esmo.org/esmo-sarcoma-and-rare-cancers-congress-2024/highlights/new-hope-for-mdm2-inhibition-in-liposarcomas

  Also important, he continues, is that brigimadlin appears to be well-tolerated at this stage […] However, cautions Serrano, we have seen a number of MDM2 inhibitors with good early-phase data fail to reproduce efficacy in later-phase trials […] The ongoing single-arm phase III Brightline-4 trial may provide further insights into the use of brigimadlin in treatment-nave or previously treated DDLPS […] It is useful to know that brigimadlin treatment for DDLPS may also shrink the WDLPS component of the disease to facilitate surgery, he concludes.

• #49 Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy

  https://www.mdpi.com/1422-0067/24/11/9571

  Immune checkpoint inhibitors (ICIs) have also been studied in WDLPS and DDLPS. […] The combination of Doxorubicin and Pembrolizumab has also been evaluated in phase I/II trials with 37 sarcoma patients. […] As illustrated above, CDK4/6 inhibitors and ICIs as monotherapy have demonstrated activity in DDLPS. However, it is not clear if the combination of these two classes of agents has synergistic activity. […] Several clinical trials for WDLPS and DDLPS are ongoing. […] The clinical trial “Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called De-differentiated Liposarcoma” is testing another MDM2 inhibitor versus doxorubicin chemotherapy. […] WDLPS and DDLPS are among the most common histological subtypes of STS. The standard systemic treatment options are limited to chemotherapeutic drugs. Recent data shows promising activity with CDK4/6 and immune checkpoint inhibitors in DDLPS. […] In addition, a number of clinical trials are evaluating the activity of small molecules targeting MDM2. Combination with a checkpoint inhibitor remains to be tested for safety and preliminary efficacy. Results from these trials shall be eagerly anticipated.

• #50 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  If the cancer has come back in the same spot or spread to only one area, we usually use chemotherapy to shrink the tumor followed by surgery, if possible. […] We use an aggressive combination of radiation therapy and chemotherapy for patients with larger tumors that have not spread. We’ve seen great results with this approach with the risk of cancer returning as low as 10% in these patients. […] Through clinical trials, we’re exploring whether we can treat some patients with myxoid liposarcoma with a type of immunotherapy called T-cell therapy or NK-cell therapy. These novel treatments use engineered receptors to modify a patients T-cells or NK cells so that these cells can recognize certain tumor-specific antigens in cancer cells and destroy them. This research will help us find better ways to target these cancer cells. […] We encourage eligible patients to enroll in these clinical trials to help advance myxoid liposarcoma treatment. Emerging therapies like these will allow us to advance myxoid liposarcoma treatment so we can help more patients.

• #51 A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report | Biomedical Research and Therapy

  http://bmrat.org/index.php/BMRAT/article/view/544

  An instance of tyrosine kinase inhibitors (TKI) is pazopanib, which is a synthetic indazolyl pyrimidine and targets VEGFR, PDGFR, and C-kit. […] Following treatment with pazopanib, lung metastasis was eradicated, and the lesion was reduced. […] The use of new therapies, such as tyrosine kinase inhibitors (pazopanib) can be effective in treating this disease.

• #52 Liposarcoma: Symptoms, Diagnosis, & Treatment Options

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

  Liposarcoma is a rare form of soft tissue sarcoma that develops in the fat cells of your stomach and limbs. Treatment of liposarcoma usually involves surgery to remove the cancer. Other treatment methods, such as chemotherapy, radiation, or a combination of treatments, may also be used. […] At Sarcoma Oncology Center, we offer personalized, cutting-edge treatment options for liposarcoma based on new studies, new trials, and innovative therapies. The treatment plan is specialized according to the requirements of each case. […] Treatment for liposarcoma may involve a multimodal approach coupled with considerations for the uniqueness of each case. This can include factors like the tumor’s grade and stage, prior cancer treatments (if any), and the disease’s progress. […] Treatment options can include: Surgery: Our oncologist may perform surgery to remove the tumor from your body. However, if liposarcoma growth is near vital organs, removal of the entire liposarcoma may not be possible.

• #53 Liposarcoma: Symptoms, Causes, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

  Radiation therapy: You may have radiation therapy to shrink the tumor before surgery, particularly if you have myxoid liposarcomas. You may also have this treatment after surgery to reduce the risk of the cancer coming back. […] Chemotherapy: Healthcare providers may use chemotherapy to treat tumors that surgery cant remove. […] Healthcare providers typically treat liposarcoma with surgery to remove the tumor and nearby healthy tissue. Any type of surgery may have complications. […] Unfortunately, you may not be able to prevent liposarcoma, particularly if you have an inherited condition that increases your risk of developing the condition. […] If you have well-differentiated liposarcoma that hasnt spread, your surgeon may be able to remove the entire tumor. If the tumor doesnt come back, your provider may consider you cured.

• #54 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  If the cancer has come back in the same spot or spread to only one area, we usually use chemotherapy to shrink the tumor followed by surgery, if possible. […] We use an aggressive combination of radiation therapy and chemotherapy for patients with larger tumors that have not spread. We’ve seen great results with this approach with the risk of cancer returning as low as 10% in these patients. […] Through clinical trials, we’re exploring whether we can treat some patients with myxoid liposarcoma with a type of immunotherapy called T-cell therapy or NK-cell therapy. These novel treatments use engineered receptors to modify a patients T-cells or NK cells so that these cells can recognize certain tumor-specific antigens in cancer cells and destroy them. This research will help us find better ways to target these cancer cells. […] We encourage eligible patients to enroll in these clinical trials to help advance myxoid liposarcoma treatment. Emerging therapies like these will allow us to advance myxoid liposarcoma treatment so we can help more patients.

• #55 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Further studies using these or completely novel treatment regimens are under investigation. […] Complete surgical resection is usually the recommended first-line treatment for localized DDL tumors. […] However, emerging studies suggest that patients with DDL tumors that are restricted to an extremity or the trunk and have a predicted 10-year tumor-related overall survival of 51% or less have improved outcomes when chemotherapy (e.g. doxorubicin plus ifosfamide) is added to their surgical regimens. […] The primary treatment option for retroperitoneal DDL is surgical resection. […] A phase III clinical trial found little difference in the results of radiation therapy followed by surgical resection compared to surgical resection alone in the treatment of retroperitoneal DDL. […] Based on these studies, a recommended first-line therapy for retroperitoneal and other surgically inaccessible or metastatic DDL tumors is treatment with an anthracycline-based chemotherapy regimen or, in tumor-resistant or relapsed cases, eribulin chemotherapy.

• #56 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  If the cancer has come back in the same spot or spread to only one area, we usually use chemotherapy to shrink the tumor followed by surgery, if possible. […] We use an aggressive combination of radiation therapy and chemotherapy for patients with larger tumors that have not spread. We’ve seen great results with this approach with the risk of cancer returning as low as 10% in these patients. […] Through clinical trials, we’re exploring whether we can treat some patients with myxoid liposarcoma with a type of immunotherapy called T-cell therapy or NK-cell therapy. These novel treatments use engineered receptors to modify a patients T-cells or NK cells so that these cells can recognize certain tumor-specific antigens in cancer cells and destroy them. This research will help us find better ways to target these cancer cells. […] We encourage eligible patients to enroll in these clinical trials to help advance myxoid liposarcoma treatment. Emerging therapies like these will allow us to advance myxoid liposarcoma treatment so we can help more patients.

• #57 Treatment of Soft Tissue Sarcomas, by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/by-stage.html

  The best chance to cure a soft tissue sarcoma is to remove it with surgery, so surgery is part of the treatment for all soft tissue sarcomas whenever possible. […] Studies have shown that people with sarcomas tend to have better outcomes when they’re treated at specialized cancer centers that have experience in sarcoma treatment. […] But in recent years, as doctors have learned more about the differences between the types, newer targeted therapy and immunotherapy drugs have become important treatment options for some types of advanced soft tissue sarcomas. […] For all stage II and III sarcomas, removing the tumor with surgery is the main treatment. […] Radiation may be given after surgery. […] The goal of treatment is to shrink the tumor, making it easier to remove. […] For people whose primary tumor and all metastases cannot be removed completely by surgery, radiation therapy and/or chemotherapy are often used.

• #58 Liposarcoma: Symptoms, Diagnosis, & Treatment Options

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

  Liposarcoma is a rare form of soft tissue sarcoma that develops in the fat cells of your stomach and limbs. Treatment of liposarcoma usually involves surgery to remove the cancer. Other treatment methods, such as chemotherapy, radiation, or a combination of treatments, may also be used. […] At Sarcoma Oncology Center, we offer personalized, cutting-edge treatment options for liposarcoma based on new studies, new trials, and innovative therapies. The treatment plan is specialized according to the requirements of each case. […] Treatment for liposarcoma may involve a multimodal approach coupled with considerations for the uniqueness of each case. This can include factors like the tumor’s grade and stage, prior cancer treatments (if any), and the disease’s progress. […] Treatment options can include: Surgery: Our oncologist may perform surgery to remove the tumor from your body. However, if liposarcoma growth is near vital organs, removal of the entire liposarcoma may not be possible.

• #59 Liposarcoma: Symptoms, Diagnosis, & Treatment Options

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

  Radiation Therapy: Radiation therapy uses energy beams to kill cancer cells. It can be used before or after the surgery to shrink the tumor or remove any cancer cells present. […] Chemotherapy: Chemotherapy involves using strong medicines to kill cancer cells. The US Food and Drug Administration (FDA) approves the use of eribulin mesylate for patients with liposarcoma. Chemotherapy may become necessary in cases where the tumor cannot be removed by surgery or has metastasized (spread from the original location to other parts). […] Clinical Trials: Clinical trials provide a chance to try the latest treatment options. Liposarcoma patients often need clinical trials or more cutting-edge treatments. Sarcoma Oncology Center is actively involved in hundreds of new studies, clinical trials, research, and innovative therapies over the years.

• #60 Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy

  https://www.mdpi.com/1422-0067/24/11/9571

  Immune checkpoint inhibitors (ICIs) have also been studied in WDLPS and DDLPS. […] The combination of Doxorubicin and Pembrolizumab has also been evaluated in phase I/II trials with 37 sarcoma patients. […] As illustrated above, CDK4/6 inhibitors and ICIs as monotherapy have demonstrated activity in DDLPS. However, it is not clear if the combination of these two classes of agents has synergistic activity. […] Several clinical trials for WDLPS and DDLPS are ongoing. […] The clinical trial “Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called De-differentiated Liposarcoma” is testing another MDM2 inhibitor versus doxorubicin chemotherapy. […] WDLPS and DDLPS are among the most common histological subtypes of STS. The standard systemic treatment options are limited to chemotherapeutic drugs. Recent data shows promising activity with CDK4/6 and immune checkpoint inhibitors in DDLPS. […] In addition, a number of clinical trials are evaluating the activity of small molecules targeting MDM2. Combination with a checkpoint inhibitor remains to be tested for safety and preliminary efficacy. Results from these trials shall be eagerly anticipated.

• #61 Advances in the targeted therapy of liposarcoma | OTT

  https://www.dovepress.com/advances-in-the-targeted-therapy-of-liposarcoma-peer-reviewed-fulltext-article-OTT

  A Phase II trial evaluating pazopanib activity in advanced and/or metastatic LPS after imatinib and sunitinib treatments is undergoing currently. […] The activation of PPAR- results in cell-cycle arrest, induction of apoptosis, inhibition of angiogenesis, and cellular redifferentiation. […] In conclusion, in the past years, a better understanding of molecular mechanisms of distinct LPS subtypes has led to the development of targeted therapy. However, we are still in the early stages of translating these findings into clinical application. More research work is needed.

• #62 Alliance –

  https://allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/News-FeaturedTrial2-June2017

  Efatutazone induces liposarcoma cell death by activating a protein called PPAR-gamma. […] Treatment for such advanced patients is generally chemotherapy, and while for many patients with liposarcomas, chemotherapy can be effective, the side effects are significant, and the benefits can be short lived. […] Alliance A091202 will study how well efatutazone dihydrochloride works in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery. […] This study is for patients age 18 and older. […] How will patients be treated on this trial? This is a single-arm study. All patients will receive efatutazone orally. Treatment will continue until disease progression or unacceptable adverse event.

• #63 Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy

  https://www.mdpi.com/1422-0067/24/11/9571

  WDLPS does not respond to systemic chemotherapy and is primarily managed with local therapy, including multiple resections and/or debulking procedures whenever clinically feasible. […] Unlike WDLPS, DDLPS can respond to chemotherapy drugs and drug combinations, including Doxorubicin (or Doxorubicin in combination with ifosfamide), gemcitabine (or gemcitabine in combination with docetaxel), trabectedin, eribulin, and pazopanib. […] In Table 1, we have outlined some of the important clinical trials involving DDLPS that have been completed, including the trials that tested CDK4/6 inhibitors and immune checkpoint inhibitors. […] Three CDK4/6 inhibitors (abemaciclib, palbociclib and ribociclib) have shown clinical benefit in patients with advanced hormone receptor (HR)-positive/HER2-negative breast cancer when given in combination with endocrine therapy. […] Despite the fact that CDK4/6 alterations are very common in many types of malignancies and that numerous preclinical studies on these agents have shown tumor suppressive effect, significant clinical benefits have only been demonstrated primarily in breast cancer and to a lesser extent, WDLPS/DDLPS.

• #64

  https://link.springer.com/article/10.1007/s11864-023-01057-4

  Myxoid/round-cell liposarcoma (MRCL) account for 30% of liposarcomas and are the most chemo-sensitive subtype of liposarcoma. The overall response rate (ORR) by RECIST with anthracycline-based chemotherapy is around 40% and with trabectedin is 20%, although response is higher when captured by CHOI criteria. Anthracycline-based combination chemotherapy regimens remain the standard of care first-line treatment option. However, trabectedin is also effective and may be considered in the first-line setting when anthracyclines cannot be prescribed. Beyond chemotherapy, new therapeutic classes are being developed, including autologous adoptive modified T cell receptor cellular therapies which have shown promising results thus far. Early phase trials have shown encouraging results with up to 40% ORR and a median progression-free survival up to 8.7 months. […] Updated NCCN guidelines include recommendation of anthracycline-based chemotherapy as first-line systemic therapy option, with trabectedin as an alternate therapeutic option.

• #65 Liposarcoma | UMass Memorial Health

  https://www.ummhealth.org/health-library/liposarcoma

  Your treatment choices depend on the type of liposarcoma you have, test results, where the tumor is, the size of the tumor, and the stage of the cancer. The goal of treatment may be to cure you, control the cancer, or to help ease problems caused by cancer. Talk with your healthcare team about your treatment choices, the goals of treatment, and what the risks and side effects may be. […] Types of treatment for cancer are either local or systemic. Local treatments remove, destroy, or control cancer cells in one area. Surgery and radiation are local treatments. Systemic treatment is used to destroy or control cancer cells that may have traveled around your body. When taken by pill or injection, chemotherapy is a systemic treatment. You may have just one treatment or a combination of treatments.

• #66 Soft Tissue Sarcoma: Liposarcoma | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma/types/liposarcoma

  Liposarcoma is a type of cancer known as soft tissue sarcoma. It begins in the fatty tissues of the body. […] The main treatment for liposarcoma is surgery to remove the tumor. Liposarcoma can begin in many different parts of the body. The surgery thats right for you depends on the exact size and location of the tumor. […] Doctors may also recommend radiation, chemotherapy, or other drug therapies. These treatments can help prevent the tumor from coming back. […] Which combination of treatments is right for you depends on the unique characteristics of the tumor. MSKs liposarcoma specialists tend to recommend radiation for people with myxoid tumors but not for people with well-differentiated tumors. Drug therapies can be beneficial, especially for myxoid and round cell tumors. […] Liposarcoma is also known for its ability to regrow after treatment. It can come back months to decades after the initial diagnosis. Thats why people should receive ongoing follow-up care to monitor for a return of liposarcoma.

• #67 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  Liposarcomas are the most common subtype of soft tissue sarcomas, accounting for at least 20% of all sarcomas in adults. […] Studies to date find that all five liposarcoma forms, while usually treatable at least initially by surgical resection, are often only marginally responsive to currently used chemotherapy and radiotherapy regimens. […] The liposarcomas require a wide range of further studies to determine their responsiveness to various radiotherapy, chemotherapy, and more novel treatment regimens as used individually and in various combinations that would include, where possible, surgical removal. […] ALT/WDL tumors are treated by radical surgical resection to remove all tumor neoplastic tissues. However, these tumors recur locally in 30-50% of cases. […] A large randomized controlled trial comparing radiotherapy followed by surgery to surgery alone in ALT/WDL tumors found little difference between the two regimens.

• #68 Treatment Strategies for Well-differentiated Liposarcomas and Therapeutic Outcomes | Anticancer Research

  https://ar.iiarjournals.org/content/32/5/1821

  This study examined 45 patients with well-differentiated liposarcoma who were surgically treated at our hospital (initial surgery in 41 patients and reoperation in 4). […] For well-differentiated liposarcomas of the limbs, it is important to establish a surgical margin beyond the marginal resection border and to perform muscle resection to the extent that would not greatly reduce the muscle strength. […] The resection margin of well-differentiated liposarcoma tends to be less than the one performed in conventional extensive resection. […] In our study, we examined therapeutic outcomes for well-differentiated liposarcoma over 20 a period of years and we also examined future treatment strategies. […] Based on these results, we concluded that resection can be performed with reduced resection margins instead of a conventional, simple extensive resection for well-differentiated liposarcoma of the limbs.

• #69 Liposarcoma: Symptoms, Causes, and Treatments

  https://www.webmd.com/cancer/what-is-liposarcoma

  Your treatment options depend on where you have the tumor, how big it is, and the type. If possible, your doctor will try to remove the tumor with surgery. This is the most common treatment for liposarcoma. […] If your tumor is growing near an important organ, or if there’s something else that prevents your doctor from removing all of the cancer during surgery, you may need to have radiation or chemotherapy after an operation to kill any cancer cells that may be left behind. […] In some cases, your doctor may suggest radiation or chemo to shrink the size of the tumor before surgery. […] You can also ask your doctor about clinical trials for people with liposarcoma. These studies test new treatments to see if they’re safe and if they work. Your doctor can let you know if you might be a good fit for one.

• #70 Soft Tissue Sarcoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq

  Effective treatment of retroperitoneal sarcomas requires removal of all gross disease while sparing adjacent viscera not invaded by tumor. […] In the setting of distant metastasis, surgery may be associated with long-term disease-free survival (DFS) in patients with pulmonary metastasis and optimal underlying disease biology. […] Chemotherapy remains controversial. […] The role of adjuvant chemotherapy remains controversial. […] The addition of ifosfamide (with mesna) to doxorubicin increases response rates and progression-free survival (PFS), but it has not been shown to improve overall survival (OS). […] Trabectedin is an FDA-approved option for second-line treatment of patients with advanced liposarcoma and leiomyosarcoma. […] Eribulin is a microtubule inhibitor that the FDA approved in 2016 to treat patients with unresectable or metastatic liposarcoma, who previously received anthracycline-containing chemotherapy. […] Immune checkpoint inhibitor therapy has shown some activity in selected soft tissue sarcoma subtypes, but the factors that may predict activity remain unknown.

• #71 Liposarcoma: Symptoms, Diagnosis, & Treatment Options

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

  At the Sarcoma Oncology Center, we recognize that liposarcoma can be difficult to treat if patients don’t respond to traditional treatment approaches. In such cases, having access to cutting-edge clinical trials or receiving approvals for 'compassionate drug use’ exceptions (access to a new unapproved medical product for patients with a serious life-threatening disease) can make a world of difference. […] At our office in Santa Monica, we design personalized and innovative plans for treating liposarcoma.

• #72 Liposarcoma: Symptoms, Diagnosis, & Treatment Options

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/

  Liposarcoma is a rare form of soft tissue sarcoma that develops in the fat cells of your stomach and limbs. Treatment of liposarcoma usually involves surgery to remove the cancer. Other treatment methods, such as chemotherapy, radiation, or a combination of treatments, may also be used. […] At Sarcoma Oncology Center, we offer personalized, cutting-edge treatment options for liposarcoma based on new studies, new trials, and innovative therapies. The treatment plan is specialized according to the requirements of each case. […] Treatment for liposarcoma may involve a multimodal approach coupled with considerations for the uniqueness of each case. This can include factors like the tumor’s grade and stage, prior cancer treatments (if any), and the disease’s progress. […] Treatment options can include: Surgery: Our oncologist may perform surgery to remove the tumor from your body. However, if liposarcoma growth is near vital organs, removal of the entire liposarcoma may not be possible.

• #73 Liposarcoma | UMass Memorial Health

  https://www.ummhealth.org/health-library/liposarcoma

  Your treatment choices depend on the type of liposarcoma you have, test results, where the tumor is, the size of the tumor, and the stage of the cancer. The goal of treatment may be to cure you, control the cancer, or to help ease problems caused by cancer. Talk with your healthcare team about your treatment choices, the goals of treatment, and what the risks and side effects may be. […] Types of treatment for cancer are either local or systemic. Local treatments remove, destroy, or control cancer cells in one area. Surgery and radiation are local treatments. Systemic treatment is used to destroy or control cancer cells that may have traveled around your body. When taken by pill or injection, chemotherapy is a systemic treatment. You may have just one treatment or a combination of treatments.

• #74 Well-Differentiated Liposarcoma – Sarcoma Oncology Center

  https://sarcomaoncology.com/types-of-sarcoma/soft-tissue-sarcomas/liposarcoma/well-differentiated-liposarcoma/

  At the Sarcoma Oncology Center, we create personalized treatment plans tailored to each case. Key factors such as the tumor’s size, location, progression, and biopsy results guide our approach. For cases of WDLS where traditional treatments are not effective, we offer access to innovative clinical trials, providing advanced options to improve outcomes.

• #75 Myxoid liposarcoma: Diagnosis, treatment and prognosis | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/myxoid-liposarcoma–diagnosis–treatment-and-prognosis.h00-159700701.html

  Myxoid liposarcoma treatment is unique to each patient. […] Treatment for myxoid liposarcoma may include surgery, radiation therapy and/or chemotherapy. […] About 50% of the time, we find myxoid liposarcoma before it has spread. We call this localized cancer. In these cases, surgery is the most common treatment. We want to remove the tumor with a rim of normal tissue surrounding it. […] Radiation therapy may be used before surgery to shrink a tumor that has not spread and to lower the risk of recurrence. It can also be used after surgery to lower the risk of recurrence. […] Chemotherapy may be used for larger tumors, more advanced myxoid liposarcoma or cancer that has come back after surgery. […] We may use chemotherapy and radiation therapy before surgery for localized tumors. Chemotherapy may be used in advanced myxoid liposarcoma to control the tumors for as long as possible when surgery is not an option.

• #76 Liposarcoma Treatment & Management: Medical Care, Consultations

  https://emedicine.medscape.com/article/1102007-treatment

  In January 2016, eribulin (Halaven), a microtubule inhibitor, was approved by the US Food and Drug Administration (FDA) for unresectable or metastatic liposarcoma in patients who received a prior anthracycline-containing regimen. […] Comprehensive genomic profiling may facilitate targeted therapy for individual liposarcomas in the future.

• #77 Histology driven systemic therapy of liposarcoma—ready for prime time? – Grethlein – Translational Gastroenterology and Hepatology

  https://tgh.amegroups.org/article/view/4712/html

  Liposarcomas are a subtype of soft tissue sarcomas arising from adipocytes. This article reviews what has been reported regarding the responsiveness of these sarcoma subtypes to traditional and newly developed systemic therapies. Overall survival for patients with advanced liposarcoma treated with systemic therapy is 16.3 months. The article addresses our progress toward the goal of improved liposarcoma outcomes through tailored interventions. Patients with liposarcoma (n=105) received first line chemotherapy with doxorubicin alone (61.8%), doxorubicin and ifosfamide (14.3%), docetaxel and gemcitabine (2.9%), docetaxel alone (2.9%) and trabectedin (2.9%). Responses were deemed complete response (CR) (3.8%), partial response (PR) (32.4%), stable disease (30.5%) and progressive disease (30.5%). The median overall survival was 16.3 months. A retrospective analysis of 16,370 patients with stage III soft tissue sarcoma treated between 1998 and 2012 in the United States was performed on the National Cancer Data Base (NCDB). There was a statistically significant (P0.001) superior overall survival for those receiving chemotherapy, compared with those who did not receive chemotherapy (82.7 versus 51.3 months). The benefit was most pronounced in pleiomorphic undifferentiated sarcoma patients. The use of molecular diagnostic techniques is better characterizing these groups. Doxorubicin, ifosfamide, gemcitabine, docetaxel, trabectedin and eribulin are now considered to be some of the most active agents in the treatment of soft tissue sarcomas in general, and liposarcoma in specific. The value of adjuvant or neoadjuvant therapy for sarcoma is tied not only to histologic subtype, but also to location. The role of adjuvant chemotherapy was studied in a phase three Italian Sarcoma Group trial in patients with high risk superficial trunk or limb soft tissue sarcoma. Patients received 3 neoadjuvant cycles of epirubicin and ifosfamide and either no additional chemotherapy or 2 cycles in the adjuvant setting. There was no significant difference in 10-year overall survival between the groups. In myxoid-round cell liposarcoma, however, relapse free survival was similar with trabectedin and the standard epirubicin with ifosfamide. In 2018, there is insufficient evidence to recommend selection of systemic therapy on the basis of the histologic subtype in most liposarcomas. An exception is MLPSs, which demonstrate particular sensitivity to trabectedin, though they generally have superior response to other agents as well.

• #78 Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment

  https://www.jcancer.org/v11p0100.htm

  The clinical study of MDM2 as a therapeutic target for WDL/DDL was reported in 2012. […] In DDL, many other potential therapeutic targets have been reported. […] Immune checkpoint inhibitors have opened up a new way for the treatment of DDL. […] In MRCL, Pollack et al. used immunohistochemistry and qPCR to detect 25 samples and found NY-ESO-1 expression in all their samples. […] It has been reported in a case that using apatinib, a small molecule inhibitor of receptor protein tyrosine kinase, targeting VEGFR-1, VEGFR-2, PDGFRB, etc., for the treatment of advanced RCL, the patient achieved PR. […] The ongoing and upcoming clinical trials of targeted therapy and immunotherapy for liposarcoma are detailed in Table 1. […] In recent years, with the extensive application of RNA library depth sequencing technology and DNA microarray technology, miRNA has become a hot spot for studying the progress and prognosis of liposarcoma. […] In the past decade, an in-depth research on the cellular and molecular pathogenesis of liposarcoma has brought about new ideas and methods for clinical diagnosis, treatment and prognosis.

• #79 Liposarcoma: Symptoms, Types, Treatment, Prognosis

  https://www.healthline.com/health/liposarcoma

  Chemotherapy is a systemic treatment involving powerful drugs to kill cancer cells. Following surgery, it can be used to destroy cancer cells that may have broken off from the primary tumor. […] After finishing treatment, you’ll need regular monitoring to make sure the liposarcoma hasn’t come back. This will likely include physical exams and imaging tests, like CT scans or MRIs. […] Clinical trials may be an option as well. These studies can give you access to newer treatments that aren’t yet available elsewhere. Ask your doctor about clinical trials that may be a good fit for you. […] Liposarcoma can be successfully treated. Once you’ve completed treatment, follow-ups should continue for at least 10 years, but perhaps for life. Your prognosis depends on many individual factors, such as the liposarcoma subtype, tumor size, stage at diagnosis, ability to get negative margins in surgery.

• #80 Liposarcoma: Symptoms, Causes, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21142-liposarcoma

  Each liposarcoma type is different, so your healthcare provider is your best resource for information about what you may expect, given your situation. In general, you may: […] Need treatment in addition to or instead of surgery. Many times, surgeons successfully treat some liposarcoma by removing the tumor. But sometimes, surgery isnt an option, which means youll need different treatment that may keep a tumor from spreading or growing but may not eliminate it. […] Need ongoing treatment to keep tumors from spreading. […] Need long-term follow-up. Once youve completed treatment, your provider will monitor your overall health and watch for any signs of new tumors. They may recommend regular follow-up appointments for at least 10 years. […] If you have a type of liposarcoma, you have a very rare form of cancer. Many times, healthcare providers can successfully treat this condition with surgery that removes and essentially cures the cancer. But some liposarcomas come back. You may need to have regular checkups for many years after completing treatment.

• #81 Myxoid Liposarcoma: Causes, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/24731-myxoid-liposarcoma

  Unfortunately, no. Most people develop myxoid liposarcoma because they had radiation therapy for other types of cancer, including lymphoma, breast cancer or prostate cancer. […] It can be placed in remission, meaning treatment eliminates all signs and symptoms of myxoid liposarcoma. But myxoid liposarcoma may come back. […] Myxoid liposarcoma may come back as new tumors where cancer first started. You may have a new myxoid liposarcoma tumor in a different area of your body. Your healthcare provider will monitor your overall health for signs of new tumors.

• #82 Childhood Liposarcoma | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/childhood-liposarcoma

  Local recurrence of the disease following surgical resection is common and may be avoided with adjuvant radiation therapy. The risk of recurrence increases with high-grade tumors. […] Children treated for liposarcoma should visit our pediatric cancer survivorship programs every year to manage disease complications, screen for early recurrence of cancer, and manage late effects of treatment.

• #83 Liposarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Liposarcoma

  A review conducted in 2020 reported median survival times for low histopathological grade and high histopathological grade DDL to be 113 months and 48 months, respectively. […] The uses of chemotherapy and/or radiotherapy in conjunction with radical surgery have not been shown to prolong survival and are regarded as controversial interventions.

• #84 Histology driven systemic therapy of liposarcoma—ready for prime time? – Grethlein – Translational Gastroenterology and Hepatology

  https://tgh.amegroups.org/article/view/4712/html

  Liposarcomas are a subtype of soft tissue sarcomas arising from adipocytes. This article reviews what has been reported regarding the responsiveness of these sarcoma subtypes to traditional and newly developed systemic therapies. Overall survival for patients with advanced liposarcoma treated with systemic therapy is 16.3 months. The article addresses our progress toward the goal of improved liposarcoma outcomes through tailored interventions. Patients with liposarcoma (n=105) received first line chemotherapy with doxorubicin alone (61.8%), doxorubicin and ifosfamide (14.3%), docetaxel and gemcitabine (2.9%), docetaxel alone (2.9%) and trabectedin (2.9%). Responses were deemed complete response (CR) (3.8%), partial response (PR) (32.4%), stable disease (30.5%) and progressive disease (30.5%). The median overall survival was 16.3 months. A retrospective analysis of 16,370 patients with stage III soft tissue sarcoma treated between 1998 and 2012 in the United States was performed on the National Cancer Data Base (NCDB). There was a statistically significant (P0.001) superior overall survival for those receiving chemotherapy, compared with those who did not receive chemotherapy (82.7 versus 51.3 months). The benefit was most pronounced in pleiomorphic undifferentiated sarcoma patients. The use of molecular diagnostic techniques is better characterizing these groups. Doxorubicin, ifosfamide, gemcitabine, docetaxel, trabectedin and eribulin are now considered to be some of the most active agents in the treatment of soft tissue sarcomas in general, and liposarcoma in specific. The value of adjuvant or neoadjuvant therapy for sarcoma is tied not only to histologic subtype, but also to location. The role of adjuvant chemotherapy was studied in a phase three Italian Sarcoma Group trial in patients with high risk superficial trunk or limb soft tissue sarcoma. Patients received 3 neoadjuvant cycles of epirubicin and ifosfamide and either no additional chemotherapy or 2 cycles in the adjuvant setting. There was no significant difference in 10-year overall survival between the groups. In myxoid-round cell liposarcoma, however, relapse free survival was similar with trabectedin and the standard epirubicin with ifosfamide. In 2018, there is insufficient evidence to recommend selection of systemic therapy on the basis of the histologic subtype in most liposarcomas. An exception is MLPSs, which demonstrate particular sensitivity to trabectedin, though they generally have superior response to other agents as well.

• #85 Liposarcoma: Symptoms, Types, Treatment, Prognosis

  https://www.healthline.com/health/liposarcoma

  According to the Liddy Shriver Liposarcoma Initiative, surgery combined with radiation therapy has been shown to prevent recurrence at the surgical site in 85 to 90 percent of cases. […] Cancer treatment is advancing quickly. It’s possible that the prognosis for someone diagnosed today is different than just a few years ago. Remember, these are general statistics and they may not represent your situation. […] Your oncologist can give you a much better idea of your outlook. […] Liposarcoma is a fairly rare type of cancer that can often be effectively treated. There are many factors that affect your specific treatment options. Talk to your doctor about the specifics of your liposarcoma to learn more about what you can expect.

• #86

  https://www.sydneysarcomaunit.com.au/liposarcoma

  Liposarcoma is a type of soft tissue tumour that starts in fat cells. […] The most common treatment for Liposarcoma is surgical removal of the tumour. This can be a challenging process, especially if your tumour is close to a vital organ. The tumour is removed with a margin on normal surrounding tissue if possible. This improves the chance of cure and reduces the risk of the tumour re-occurring. […] In select cases, the treating team may recommend radiation therapy or chemotherapy before your surgery to help shrink your tumour. […] The use of radiotherapy for these tumours in controversial. It is used in very select cases dependant on the type of liposarcoma (myxoid) and the location. Radiotherapy is more useful in the management of metastatic disease. […] Liposarcomas are resistant to most chemotherapy agents and there is no role for routine chemotherapy after surgery. Chemotherapy is reserved for when there is metastatic disease. […] Outcomes for liposarcoma vary widely depending on the pathological subtype and location of the tumour. Myxoid and Well differentiated liposarcomas have the best outcomes when comparing the different subtypes; as do tumours that arise in the limbs compared with those arising in the abdomen.

Zobacz więcej